Linked Life Data

16272621

Source:http://linkedlifedata.com/resource/pubmed/id/16272621

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2005-11-7
pubmed:abstractText
The data on magnesium supplementation in patients with acute myocardial infarction (AMI) is conflicting. Although a number of relatively small randomized clinical trials have demonstrated a remarkable reduction in mortality when administered to relatively high risk AMI patients, two recently published large-scale randomized clinical trials (the Fourth International Study of Infarct Survival and Magnesium in Coronaries) failed to show any superiority of intravenous magnesium over placebo. Nevertheless, the theoretical potential benefits of magnesium supplementation as a cardioprotective agent in coronary artery disease (CAD) patients, in conjunction with previous promising results from work in animal and humans, its relatively low cost, easy administration, with no need for special expertise, and relatively free of adverse effects, gives magnesium a place in treating CAD patients, especially high-risk groups such as CAD patients with heart failure, the elderly and hospitalized patients with hypomagnesemia.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0917-5857
pubmed:author
pubmed:issnType
Print
pubmed:volume
15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
111-5
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Magnesium and myocardial infarction.
pubmed:affiliation
Heart Institute, Sheba Medical Center, Tel-Hashomer, Israel. shechter@sheba.health.gov.il
pubmed:publicationType
Journal Article, Review